First-line second generation tyrosine kinase inhibitors in patients with newly diagnosed accelerated phase chronic myeloid leukemia

Balsat, Marie; Alcazer, Vincent; Etienne, Gabriel; Huguet, Françoise; Berger, Marc; Cayssials, Emilie; Charbonnier, Aude; Escoffre-Barbe, Martine; Johnson-Ansah, Hyacinthe; Legros, Laurence; Roy, Lydia; Delmer, Alain; Ianotto, Jean-Christophe; Orvain, Corentin; Larosa, Fabrice; Meunier, Mathieu; Amé, Shanti; Andreoli, Annalisa; Cony-Makhoul, Pascale; Morisset, Stéphane; Tigaud, Isabelle; Rea, Delphine; Nicolini, Franck Emmanuel

doi:10.1016/j.leukres.2023.107308

First-line second generation tyrosine kinase inhibitors in patients with newly diagnosed accelerated phase chronic myeloid leukemia

Accelerated phase (AP) CML at onset and have poorer prognosis than CP-CML. We hypothesize that off-license use of second generation TKI (TKI2) as front-line therapy might counterbalance this poor prognosis, with limited toxicity. In "real-life" conditions, newly diagnosed patients meeting the ELN…